ENANTA PHARMACEUTICALS INC — Director's Dealing 2018

Jun 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2018-06-18

Reporting Person: Adda Nathalie (Sr. VP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-18	Common Stock	M	2955	$43.46	Acquired	7755	Direct
2018-06-18	Common Stock	S	1268	$113.9008	Disposed	6487	Direct
2018-06-18	Common Stock	S	2229	$115.0929	Disposed	4258	Direct
2018-06-18	Common Stock	S	658	$115.8874	Disposed	3600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-18	Stock Option (Right to Buy)	$43.46	M	2955	Disposed	2025-06-29	Common Stock (2955)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $113.44 to $114.28, inclusive.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $114.55 to $115.51, inclusive.

F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $115.65 to $116.08, inclusive.

F5: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.